

Butler, Jennie C

From: Ron Warren [Ron.Warren@advancedtissue.com]
Sent: Tuesday, June 11, 2002 7:19 PM
To: 'FDADockets@oc.fda.gov'
Subject: Notice of Participation - Dr. Michael McGuire



McGuire Notice of
Participatio...

02N-0169

APR 11

TO: Dockets Management Branch (HFA-305)

FROM: Michael McGuire, D.D.S.

DATE: June 11, 2002

SUBJECT: Docket No. 02N-0169: Notice of Participation, Public Hearing on
Combination Products Containing Live Cellular Components

By this notice, I am requesting the opportunity to participate in the June 24, 2002 public hearing on combination products containing live cellular components that are intended for wound healing.

Provided below is the specific information requested in the FDA's Federal Register notice:

1. Name/Address: Michael K. McGuire, D.D.S.
3400 S. Gessner, #102
Houston, TX 77063
PH (713) 783-5442
FAX (713) 952-0614
2. Affiliation: Private practice;
Clinical Assistant Professor
Department of Periodontics
University of Texas Dental Branch
San Antonio, TX
(curriculum vitae attached)
3. I am being sponsored by Advanced Tissue Sciences, Inc., who is covering the cost of my travel expenses.
4. Brief summary of presentation:

As a practicing periodontist, clinical professor in the area of periodontics, and past President of the American Academy of Periodontology, my presentation will address periodontal uses of cellular wound healing products, the importance of these products to periodontal patients and the health care community, and why device regulation of these products has fostered innovation. I request 10 minutes for this presentation.

Butler, Jennie C

From: Jim Hogan [jhogan@mdxn.ch]
Sent: Wednesday, June 12, 2002 3:13 AM
To: Dockets Management Branch
Cc: Vincent Ronfard
Subject: Combination cellular components hearing

Dear Sir,
I wish to participate in the COMBINATION PRODUCTS CONTAINING LIVE CELLULAR COMPONENTS HEARING which will take place at the Doubletree hotel on June 24.
Joining me will be our Director of Research, Dr. Vincent Ronfard.
We will be observing the meeting, and do not plan to make a specific presentation at this time. My company affiliation and contact details are listed below.
Kind Regards,
Jim Hogan

Jim Hogan
Chief Operating Officer
Modex Therapeutics Ltd
18 Avenue de Sévelin
1004 Lausanne, Switzerland
tel: +41 21 6206035
fax: +41 21 6206060
mobile: +41 79 704 8955
e-mail jhogan@mdxn.ch